Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

Vaccinations

Vaccinations

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Surveillance and vaccine effectiveness of pertussis, the Netherlands, 2012 to 2024, with an unprecedented surge in 2023 and 2024.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026

Same author

No improvement in parental vaccine hesitancy in the Netherlands in 2023 versus 2022.

BMC public health·2026

Same author

Antibody waning and Bordetella pertussis resurgence after the COVID-19 pandemic in the Netherlands.

Nature communications·2026

Same author

Large differences in MMR and DTaP-IPV vaccination coverage among primary schools by denomination, the Netherlands, 2024.

Vaccine·2025

Same author

The decrease in childhood vaccination coverage and its sociodemographic determinants, the Netherlands, birth cohorts 2008 to 2020.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2025

Same author

Determinants for not keeping up to date with COVID-19 vaccination in the 2023 vaccination round among medical risk groups, the Netherlands.

Vaccine·2025

Search research articles

Related Experiment Video

Updated: May 16, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

[Developments in HPV vaccination].

Hester de Melker¹, Gemma Kenter, Tekla van Rossum

¹Centrum Infectieziektebestrijding, RIVM, Bilthoven, the Netherlands.

Nederlands Tijdschrift Voor Geneeskunde

|November 23, 2012

Summary

Human papillomavirus (HPV) vaccination for 12-year-old girls in the Netherlands shows increasing uptake and is cost-effective. Monitoring confirms no new serious side effects, with transient symptoms being common.

Area of Science:

Public Health
Immunology
Oncology

Context:

The Netherlands introduced human papillomavirus (HPV) vaccination into its national program for 12-year-old girls in 2010.
Initial vaccination coverage for the 1997 birth cohort was 56%, with a gradual increase observed over time.

Purpose:

To assess the safety, effectiveness, and cost-effectiveness of HPV vaccination within the Dutch national program.
To evaluate the broader implications of HPV vaccination beyond cervical cancer prevention.

Summary:

Continuous safety monitoring has not revealed new serious side effects, although transient symptoms like arm pain, fatigue, and headache are reported.
Current vaccines protect against HPV types 6 and 11, with ongoing development of vaccines offering broader protection.

More Related Videos

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Related Experiment Videos

Last Updated: May 16, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

HPV vaccination is cost-effective, even at lower coverage rates, and offers protection against various HPV-related oncological manifestations and genital warts in both sexes.

Impact:

HPV vaccination demonstrates significant public health benefits by preventing oncological manifestations and genital warts.
The findings support the continued implementation and potential expansion of HPV vaccination programs.
Preventive HPV vaccines are not effective for treating existing HPV-related abnormalities.